本帖最后由 maicon08 于 2023-4-28 15:12 编辑 5 g' h3 x: t' a: D
$ r7 X- b/ `2 B( M
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。
! a7 M" w; @$ U6 z. t2 K$ R& p* c6 j5 ~8 F2 U+ A$ b3 A
https://www.163.com/dy/article/I3BTTPRD053438SI.html
" `: I& \% z2 V- G- n8 C# |' u; P- B/ w6 g7 l# ?3 k7 V
# }. X# h: F7 b6 ?4 G在研疗法-免疫治疗; {3 K( _. Q5 R% D& n; X }
Developmental Therapeutics—Immunotherapy0 ^0 {/ A! k; r- u- {
$ Z" z( E8 H/ f3 j, R摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心
7 X: s* X& ]4 J) w# Y+ e. m. x
在研疗法-分子靶向药物和肿瘤生物学3 {6 ^3 H3 A3 C% c' i4 ?
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology 0 J' T/ g, ]% L/ Q
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心 $ Q# c: \8 G8 N+ s! W
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院 ! G! _& j+ k, z( q
胃肠道肿瘤-结直肠癌和肛门癌5 K \% s3 a: c( H! i' B! }3 |
Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院 + Y% _; ~! I' I3 f- v( C
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary + `9 h/ z# Q+ c! u
摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心 W( X, z. ]8 } h) ]" M: ] L
妇科肿瘤 Gynecologic Cancer $ S' R2 }; e2 f
摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院 7 x- [. y0 x4 }' |
头颈肿瘤
! n' w( _# M3 [- x$ ?6 i' ` Head and Neck Cancer ' t. p7 }1 ]6 X- E
摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心 7 J& Z6 |2 a" g- ]+ y7 C. s; i
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心
0 j: y4 t" K+ p4 ?
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 $ X: J6 R$ S/ s, d J+ F
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
: y* T$ y6 e3 |; }摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心 + V, E3 g$ H+ k6 g- y; |! b B" `
血液系统恶性肿瘤-浆细胞疾病, g, Y+ q' r5 C8 f4 K
Hematologic Malignancies—Plasma Cell Dyscrasia ! }% d8 d# `, q* \& a
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院 2 ]) i1 A5 K7 D6 F7 v# W6 [
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
2 s- k( Q/ D( P# t; u- i0 | Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ( _& K J% ]# ^7 N; a% q! R
摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院 : q5 P( [' ]: b' A0 K V. g# B
肺癌-转移性非小细胞肺癌( O1 X2 c* h# b
Lung Cancer—Non-Small Cell Metastatic ( a7 N% c) h0 t4 l4 f
摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院
8 z$ W+ L' E# l; E6 @- G6 P4 Q& [
' @& M# d8 x- F9 j% C+ |+ ~摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院 " Q3 ~& c" N9 ^
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院 $ u7 g/ o P2 J' B# R$ e V7 _8 `
黑色素瘤/皮肤癌
7 \7 h0 `9 C% j! J2 J) C Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院
( l8 a# }' |$ z' j' B6 u
快速摘要报告+ `. S% @ @- X a# H
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心
, n+ {7 {; i) |) ~7 Z6 u
临床科学研讨会# z( R, K i* x# L
Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院
3 G0 _2 g& M! M( o' J0 _
* O* C0 ^" B( \) ]' } W | 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
